SummaryThis study was conducted to evaluate the safety and efficacy of tolvaptan following open heart surgery. We retrospectively reviewed 109 patients who were administered tolvaptan following open heart surgery between August 2011 and July 2014. We divided the patients according to their urine output index (amount of urine output/body surface area) into tertiles as follows: T1 (low responders; n = 36), T2 (intermediate responders; n = 36), and T3 (high responders; n = 37). No fatal adverse events were observed following tolvaptan administration. The factors that showed a significant difference among the 3 groups were body surface area (BSA) and preoperative body weight. Body weight rapidly decreased and a greater increase in the serum sodium level was observed on day 1 in the T3 group than in the other 2 groups. No decrease in blood pressure and no significant differences in the occurrence of atrial fibrillation were observed among the 3 groups during tolvaptan administration.Tolvaptan can be safely and effectively administered to increase the urine output without adversely affecting the cardiovascular system or renal function following open heart surgery. However, careful attention is required regarding the possibility of a rapid increase in the serum sodium level so it is important to monitor changes in serum Na levels. ( open heart surgery in recent years, volume control is one of the most important factors in the perioperative management of open heart surgery. Tolvaptan, a vasopressin V2-receptor antagonist, is available as a diuretic drug that can be used in the treatment of fluid accumulation in heart failure. Several studies have reported the efficacy of tolvaptan in patients with chronic congestive heart failure and acute heart failure. [1][2][3][4][5] According to previous reports, the use of tolvaptan for acute heart failure at an early stage of hospitalization prevents exacerbation of acute kidney injury, improves patient prognosis, 6) is superior to carperitide in terms of treatment cost of acute heart failure, 7) and is effective for correcting hyponatremia. [8][9][10] Although there are case reports indicating the efficacy of tolvaptan after open heart surgery, the number of patients reported is small. [11][12][13][14] Open heart surgery using cardiopulmonary bypass is often followed by symptoms such as circulatory inflammatory response, capillary hyperpermeability due to low body temperature, decreased intravascular colloid oncotic pressure due to hemodilution, and stromal edema as a result of decreased lymph flow.15) Blood vasopressin concentration also increases after cardiac surgery because of hypotension during cardiopulmonary bypass and sympathetic nerve activation caused by operative stress.16) Therefore, it is believed that reabsorption of water in the collecting tubules is excessive following open heart surgery. Because the diuretic effect of tolvaptan reduces the accumulation of intercellular fluid through an increase in the serum Na level or a difference in osmotic pressure, tolvaptan ...